Cargando…

Analysis of the association of HER-2 low carcinomas and PAM50 assay in hormone receptor positive early-stage breast cancer

BACKGROUND: HER2-low has emerged as a new predictive biomarker in metastatic breast cancer. However, its prognostic value in early-stage carcinomas needs to be revisited. We aimed to evaluate the association of HER2-low carcinomas with PAM50 risk groups combined with clinicopathological variables in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Terán, Santiago, Alva, Manuel, Tolosa, Pablo, Rey-Cárdenas, Macarena, Madariaga, Ainhoa, Lema, Laura, Ruano, Yolanda, Manso, Luis, Ciruelos, Eva, Sánchez-Bayona, Rodrigo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10392598/ https://www.ncbi.nlm.nih.gov/pubmed/37481795 http://dx.doi.org/10.1016/j.breast.2023.07.009

Ejemplares similares

Digging into phenotype change in mismatch repair deficient endometrial carcinoma and treatment with immune checkpoint inhibition, a case report
por: Rey-Cárdenas, Macarena, et al.
Publicado: (2023)

Reproducibility and intratumoral heterogeneity of the PAM50 breast cancer assay
por: Hurson, Amber N., et al.
Publicado: (2023)

Expression of PAM50 Genes in Lung Cancer: Evidence that Interactions between Hormone Receptors and HER2/HER3 Contribute to Poor Outcome()()
por: Siegfried, Jill M., et al.
Publicado: (2015)

38P Impact of 1-year COVID-19 pandemic in patients with ovarian carcinoma treated with chemotherapy based on a global data network
por: Manso Sanchez, L.M., et al.
Publicado: (2022)

Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer
por: Schettini, Francesco, et al.
Publicado: (2021)

Role of Intrinsic Subtype Analysis with PAM50 in Hormone Receptors Positive HER2 Negative Metastatic Breast Cancer: A Systematic Review
por: Canino, Fabio, et al.
Publicado: (2022)

Development and verification of the PAM50-based Prosigna breast cancer gene signature assay
por: Wallden, Brett, et al.
Publicado: (2015)

Author Correction: Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer
por: Schettini, Francesco, et al.
Publicado: (2023)

TP53 Mutational Analysis Enhances the Prognostic Accuracy of IHC4 and PAM50 Assays
por: Lin, Ching-Hung, et al.
Publicado: (2015)

A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer
por: Pascual, Tomás, et al.
Publicado: (2019)

Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancer
por: Fernand ez-Martinez, Aranzazu, et al.
Publicado: (2017)

PAM50 assay and the three-gene model for identifying the major and clinically relevant molecular subtypes of breast cancer
por: Prat, A., et al.
Publicado: (2012)

Characterization of uncertainty in the classification of multivariate assays: application to PAM50 centroid-based genomic predictors for breast cancer treatment plans
por: Ebbert, Mark TW, et al.
Publicado: (2011)

PAM50 Subtypes in Baseline and Residual Tumors Following Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer: A Consecutive-Series From a Single Institution
por: Pernas, Sonia, et al.
Publicado: (2019)

Research-based PAM50 signature and long-term breast cancer survival
por: Pu, Minya, et al.
Publicado: (2019)

A comparative study of PCS and PAM50 prostate cancer classification schemes
por: Yoon, Junhee, et al.
Publicado: (2021)

Neratinib, an irreversible pan erB receptor tyrosine kinase inhibitor active for advanced HER2(+ )breast cancer
por: Cortés-Funes, H, et al.
Publicado: (2009)

Corrigendum: PAM50 Subtypes in Baseline and Residual Tumors Following Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer: A Consecutive-Series From a Single Institution
por: Pernas, Sonia, et al.
Publicado: (2019)

PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer
por: Martín, Miguel, et al.
Publicado: (2013)

Association of high obesity with PAM50 breast cancer intrinsic subtypes and gene expression
por: Kwan, Marilyn L, et al.
Publicado: (2015)

Robust and interpretable PAM50 reclassification exhibits survival advantage for myoepithelial and immune phenotypes
por: Mathews, James C., et al.
Publicado: (2019)

Multi-Omic Regulation of the PAM50 Gene Signature in Breast Cancer Molecular Subtypes
por: Ochoa, Soledad, et al.
Publicado: (2020)

Perturbation and stability of PAM50 subtyping in population-based primary invasive breast cancer
por: Veerla, Srinivas, et al.
Publicado: (2023)

Different Pathological Complete Response Rates According to PAM50 Subtype in HER2+ Breast Cancer Patients Treated With Neoadjuvant Pertuzumab/Trastuzumab vs. Trastuzumab Plus Standard Chemotherapy: An Analysis of Real-World Data
por: Díaz-Redondo, Tamara, et al.
Publicado: (2019)

Genetic Background May Contribute to PAM50 Gene Expression Breast Cancer Subtype Assignments
por: Hu, Ying, et al.
Publicado: (2013)

Sample Preparation Approach Influences PAM50 Risk of Recurrence Score in Early Breast Cancer
por: Lien, Tonje G., et al.
Publicado: (2021)

Discordance between PAM50 intrinsic subtyping and immunohistochemistry in South African women with breast cancer
por: Dix-Peek, Thérèse, et al.
Publicado: (2023)

PAM-50 predicts local recurrence after breast cancer surgery in postmenopausal patients with ER+/HER2– disease: results from 1204 patients in the randomized ABCSG-8 trial
por: Fitzal, F, et al.
Publicado: (2021)

PAM-50 predicts local recurrence after breast cancer surgery in postmenopausal patients with ER+/HER2– disease: results from 1204 patients in the randomized ABCSG-8 trial
Publicado: (2021)

PAM50 Breast Cancer Subtyping by RT-qPCR and Concordance with Standard Clinical Molecular Markers
por: Bastien, Roy RL, et al.
Publicado: (2012)

Gene modules associated with breast cancer distant metastasis-free survival in the PAM50 molecular subtypes
por: Liu, Rong, et al.
Publicado: (2016)

The LEPSIS Pam-File
por: DELPHI Collaboration
Publicado: (1982)

PAM50 subtyping and ROR score add long-term prognostic information in premenopausal breast cancer patients
por: Lundgren, Christine, et al.
Publicado: (2022)

Modifications to the LEPSIM Pam-File
por: DELPHI Collaboration
Publicado: (1982)

El Pim-pam-pum
por: Ionesco, Eugène

GPR40 partial agonists and AgoPAMs: Differentiating effects on glucose and hormonal secretions in the rodent
por: Pachanski, Michele J., et al.
Publicado: (2017)

Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine
por: Asleh, Karama, et al.
Publicado: (2023)

The Prediction Analysis of Microarray 50 (PAM50) Gene Expression Classifier Utilized in Indeterminate-Risk Breast Cancer Patients in Hungary: A Consecutive 5-Year Experience
por: Dank, Magdolna, et al.
Publicado: (2023)

Comparative Analysis of Putative Orthologues of Mitochondrial Import Motor Subunit: Pam18 and Pam16 in Plants
por: Chen, Xuejin, et al.
Publicado: (2013)

Analytical validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay and nCounter Analysis System using formalin-fixed paraffin-embedded breast tumor specimens
por: Nielsen, Torsten, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_hf60t6rtqu9b1r4fthku237l2m